SPINAL MUSCULAR ATROPHY AS A MOLECULAR-NEUROLOGICAL DISORDER. SMN1 DYSFUNCTION, MOTOR NEURON DEGENERATION AND THE CLINICAL VALUE OF EARLY DIAGNOSIS
Keywords:
spinal muscular atrophy, SMN1 gene, SMN2 gene, SMN protein, motor neuron degeneration, gene therapy, newborn screening, neuromuscular diseaseAbstract
Spinal muscular atrophy is a genetically determined neuromuscular disease in which dysfunction of the SMN1 gene causes a systemic deficiency of survival motor neuron protein and selective vulnerability of lower motor neurons. Although the molecular defect is present in all nucleated cells, the most clinically important consequences occur in the anterior horn cells of the spinal cord and in the neuromuscular junction. This review article analyzes the relationship between SMN1 loss, altered SMN2 splicing, RNA-processing defects, axonal transport failure, synaptic instability, and progressive muscle denervation in a structured IMRAD format. The literature review emphasizes that the introduction of nusinersen, onasemnogene abeparvovec and risdiplam has changed the natural history of the disease, but therapeutic benefit remains strongly dependent on the number of viable motor neurons at the time of treatment. Therefore, newborn screening and presymptomatic diagnosis are presented as central clinical strategies rather than optional diagnostic additions. The article also discusses current limitations of disease-modifying therapy, including incomplete recovery in advanced disease, the need for long-term safety monitoring, economic barriers and unequal access to screening. The findings support an integrated molecular-clinical approach in which genetic confirmation, early referral, multidisciplinary care and timely treatment are combined to reduce irreversible neurological disability.
References
1.Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., Le Paslier, D., Frézal, J., Cohen, D., Weissenbach, J., Munnich, A., & Melki, J. (1995). Identification and characterization of a spinal muscular atrophy-determining gene. Cell, 80(1), 155-165.
2.Burghes, A. H. M., & Beattie, C. E. (2009). Spinal muscular atrophy. Why do low levels of SMN protein cause motor neuron disease. Nature Reviews Neuroscience, 10(8), 597-609.
3.Mercuri, E., Finkel, R. S., Muntoni, F., Wirth, B., Montes, J., Main, M., Mazzone, E. S., Vitale, M., Snyder, B., Quijano-Roy, S., Bertini, E., Davis, R. H., Meyer, O. H., Simonds, A. K., Schroth, M. K., Graham, R. J., Kirschner, J., Iannaccone, S. T., Crawford, T. O., Woods, S., Qian, Y., & Sejersen, T. (2018). Diagnosis and management of spinal muscular atrophy. Part 1. Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. The Lancet Neurology, 17(8), 689-701.
4.Mercuri, E., Finkel, R. S., Muntoni, F., Wirth, B., Montes, J., Main, M., Mazzone, E. S., Vitale, M., Snyder, B., Quijano-Roy, S., Bertini, E., Davis, R. H., Meyer, O. H., Simonds, A. K., Schroth, M. K., Graham, R. J., Kirschner, J., Iannaccone, S. T., Crawford, T. O., Woods, S., Qian, Y., & Sejersen, T. (2018). Diagnosis and management of spinal muscular atrophy. Part 2. Pulmonary and acute care, medications, supplements and immunizations, other organ systems, and ethics. The Lancet Neurology, 17(8), 702-716.
5.Verhaart, I. E. C., Robertson, A., Wilson, I. J., Aartsma-Rus, A., Cameron, S., Jones, C. C., Cook, S. F., & Lochmüller, H. (2017). Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy. A literature review. Neuromuscular Disorders, 27(10), 842-851.
6.Oskoui, M., Darras, B. T., & De Vivo, D. C. (2017). Spinal muscular atrophy. 125 years later and on the verge of a cure. JAMA Neurology, 74(4), 420-421.
7.Tisdale, S., & Pellizzoni, L. (2015). Disease mechanisms and therapeutic approaches in spinal muscular atrophy. The Journal of Neuroscience, 35(23), 8691-8700.
8.Kolb, S. J., & Kissel, J. T. (2015). Spinal muscular atrophy. Neurologic Clinics, 33(4), 831-846.
9.Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., Topaloglu, H., Tulinius, M., Montes, J., Glanzman, A. M., Bishop, K., Zhong, Z. J., Gheuens, S., Bennett, C. F., Schneider, E., Farwell, W., & De Vivo, D. C. (2017). Nusinersen versus sham control in later-onset spinal muscular atrophy. The New England Journal of Medicine, 377(18), 1723-1732.
10.Mercuri, E., Darras, B. T., Chiriboga, C. A., Day, J. W., Campbell, C., Connolly, A. M., Iannaccone, S. T., Kirschner, J., Kuntz, N. L., Saito, K., Shieh, P. B., Tulinius, M., Mazzone, E. S., Montes, J., Bishop, K. M., Yang, Q., Foster, R., Gheuens, S., Bennett, C. F., Farwell, W., & De Vivo, D. C. (2018). Nusinersen versus sham control in infants with spinal muscular atrophy. The New England Journal of Medicine, 378(7), 625-635.
11.Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., Kissel, J. T., Nagendran, S., L'Italien, J., Sproule, D. M., Wells, C., Cardenas, J. A., Heitzer, M. D., Kaspar, A., Corcoran, S., Braun, L., Likhite, S., Miranda, C., Meyer, K., Foust, K. D., Burghes, A. H. M., & Kaspar, B. K. (2017). Single-dose gene-replacement therapy for spinal muscular atrophy. The New England Journal of Medicine, 377(18), 1713-1722.
12.Baranello, G., Darras, B. T., Day, J. W., Deconinck, N., Klein, A., Masson, R., Mercuri, E., Rose, K., El-Khairi, M., Gerber, M., Gorni, K., Khwaja, O., Kletzl, H., Scalco, R. S., & Servais, L. (2021). Risdiplam in type 1 spinal muscular atrophy. The New England Journal of Medicine, 384(10), 915-923.
13.Mercuri, E., Baranello, G., Boespflug-Tanguy, O., De Waele, L., Goemans, N., Kirschner, J., Kostera-Pruszczyk, A., Masson, R., Meyer, O. H., Muntoni, F., Pane, M., Pechmann, A., Sansone, V. A., Servais, L., & Darras, B. T. (2022). Risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy. The Lancet Neurology, 21(1), 42-52.
14.Hagenacker, T., Wurster, C. D., Günther, R., Schreiber-Katz, O., Osmanovic, A., Petri, S., Weiler, M., Ziegler, A., Kuttler, J., Koch, J. C., Schneider, I., Wunderlich, G., Uzelac, Z., & Ludolph, A. C. (2020). Nusinersen in adults with 5q spinal muscular atrophy. The Lancet Neurology, 19(4), 317-325.
15.Verhaart, I. E. C., & Aartsma-Rus, A. (2019). Therapeutic developments for spinal muscular atrophy. Nature Reviews Neurology, 15(9), 544-556.
16.Pechmann, A., & Kirschner, J. (2017). Diagnosis and new treatment avenues in spinal muscular atrophy. Current Neurology and Neuroscience Reports, 17, 49.
17.Darras, B. T. (2015). Spinal muscular atrophies. Pediatric Clinics of North America, 62(3), 743-766.
18.Strauss, K. A., Farrar, M. A., Muntoni, F., Saito, K., Mendell, J. R., Servais, L., McMillan, H. J., Finkel, R. S., Swoboda, K. J., Kwon, J. M., Zaidman, C. M., & Day, J. W. (2021). Newborn screening for spinal muscular atrophy. Pediatrics, 148(1), e2021050018.
19.Kay, D. M., Stevens, C. F., Parker, A., Saavedra-Matiz, C. A., Sack, V., Chung, W. K., & Wasserstein, M. P. (2020). Implementation of population-based newborn screening reveals low incidence of spinal muscular atrophy. Genetics in Medicine, 22(6), 1022-1029.
20.Glascock, J., Sampson, J., Haidet-Phillips, A., Connolly, A. M., Darras, B. T., Day, J. W., Finkel, R. S., Howell, R. R., Klinger, K. W., Kuntz, N., Prior, T. W., Shieh, P. B., & Crawford, T. O. (2018). Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening. Journal of Neuromuscular Diseases, 5(2), 145-158.
21.Al-Zaidy, S. A., Kolb, S. J., Lowes, L., Alfano, L., Shell, R., Church, K. R., Nagendran, S., Sproule, D. M., Feltner, D. E., Wells, C., Prior, T. W., & Mendell, J. R. (2019). AVXS-101 gene replacement therapy for spinal muscular atrophy. Immune response and safety considerations. Molecular Therapy, 27(5), 875-884.
22.Walter, M. C., Wenninger, S., Thiele, S., Staerk, C., Pechmann, A., Hagenacker, T., & Schoser, B. (2023). Safety monitoring of disease-modifying therapies in spinal muscular atrophy. Therapeutic Advances in Neurological Disorders, 16, 1-14.
23.Sansone, V. A., Walter, M. C., Attarian, S., Delstanche, S., & Servais, L. (2022). Quality of life in treated spinal muscular atrophy. Journal of Neurology, 269(3), 1357-1368.
24.Strauss, K. A., Carson, V. J., Brigatti, K. W., Young, M., Robinson, D. L., Hendrickson, C., & Puffenberger, E. G. (2023). Sustained outcomes following presymptomatic treatment of spinal muscular atrophy identified through newborn screening. Pediatrics, 152(2), e2022059506.
25.Qu, Y., Zhou, J., Wang, Y., Wang, X., & Chen, Y. (2023). Cost-effectiveness of therapies for spinal muscular atrophy. Health Economics Review, 13, 22.
26.Aartsma-Rus, A., & Verhaart, I. E. C. (2025). Next-generation therapeutic strategies for spinal muscular atrophy. Nature Reviews Neurology, 21(1), 15-28.




United Kingdom
Germany
France
Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo
Italy
Spain
Poland
Netherlands
Belgium
Sweden
Norway
Finland
Denmark
Switzerland
Austria
Czech Republic
Hungary
Romania
Bulgaria
Greece
Portugal